Analysis of acquired resistance mechanisms to next-generation kinase inhibitors in lung cancers with EGFR mutation.

2014 Fiscal Year Final Research Report

• Project/Area Number: 25830119
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics
• Research Institution: Kinki University
• Principal Investigator: SUDA Kenichi 近畿大学, 医学部, 助教 (30631593)
• Research Collaborator: MIZUUCHI Hiroshi ; SATO Katsuaki
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: 分子標的薬 / 肺癌 / 耐性 / EGFR変異 / 個別化治療

Outline of Final Research Achievements

EGFR kinase inhibitors are the key drugs in the treatment of lung cancer patients with EGFR activating mutations. However, emergence of acquired resistance to these drugs is almost inevitable. There are several unanswered issues to establish best treatment strategies after acquisition of resistance to EGFR kinase inhibitors. These include, (1) if chemosensitivity alters after acquisition of resistance, (2) novel resistance mechanisms other than T790M mutation. MET amplification, ERBB2 amplification, etc, and (3) molecular mechanisms that confer acquired resistance to next-generation EGFR kinase inhibitors. In this work, we analyzed these points, mainly using in vitro models.

Free Research Field

腫瘍学